Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHEN G DIVERS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1760469407
CMS profile
353046
Location
HOT SPRINGS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$8,517.27

176 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,213.00 5
Food and Beverage $3,293.43 170
Travel and Lodging $10.84 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Daiichi Sankyo Inc. $1,807.47 4
Pharmacosmos Therapeutics Inc. $1,726.60 13
AstraZeneca Pharmaceuticals LP $1,597.56 11
Spectrum Pharmaceuticals Inc. $804.50 4
Novartis Pharmaceuticals Corporation $241.58 18
Eisai Inc. $170.30 3
Merck Sharp & Dohme LLC $148.38 8
GlaxoSmithKline, LLC. $146.67 7
Seagen Inc. $142.81 8
PFIZER INC. $140.01 9
Celgene Corporation $138.25 14
GENZYME CORPORATION $99.33 5
Janssen Scientific Affairs, LLC $97.25 1
Janssen Biotech, Inc. $94.76 6
MorphoSys, US Inc. $88.20 5
AbbVie Inc. $87.11 5
Exelixis Inc. $78.71 4
Sumitomo Pharma America, Inc. $67.39 3
E.R. Squibb & Sons, L.L.C. $67.21 3
ARRAY BIOPHARMA INC $50.52 2
Astellas Pharma US Inc $49.24 3
Incyte Corporation $47.85 3
Bayer Healthcare Pharmaceuticals Inc. $44.60 2
BeiGene USA, Inc. $42.85 3
ADC Therapeutics America, Inc. $41.11 2
Kite Pharma, Inc. $39.60 2
Gilead Sciences, Inc. $32.03 2
Stemline Therapeutics Inc. $31.47 2
Lilly USA, LLC $31.39 2
Pharmacyclics LLC, An AbbVie Company $31.13 2
Mirati Therapeutics, Inc. $30.87 2
Rigel Pharmaceuticals, Inc. $30.81 2
Takeda Pharmaceuticals U.S.A., Inc. $28.62 1
Genentech USA, Inc. $27.69 2
TerSera Therapeutics LLC $22.89 1
Puma Biotechnology, Inc. $20.62 1
Apellis Pharmaceuticals, Inc. $20.46 1
SOBI, INC $19.60 1
Karyopharm Therapeutics Inc. $18.71 1
Regeneron Healthcare Solutions, Inc. $15.79 1
AVEO Pharmaceuticals, Inc. $15.37 1
Acrotech Biopharma Inc. $14.91 1
G1 Therapeutics, Inc. $13.86 1
Shield Therapeutics Inc $12.90 1
Genmab U.S., Inc. $12.81 1
EMD Serono, Inc. $12.74 1
Sun Pharmaceutical Industries Inc. $12.74 1

Page 3 of 4; records 101–150 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHEN G DIVERS

NPI 1760469407 · CMS profile ID 353046

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

HOT SPRINGS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760469407?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHEN G DIVERS, NPI 1760469407, CMS profile ID 353046. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760469407?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). STEPHEN G DIVERS, NPI 1760469407, CMS profile ID 353046. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760469407?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
STEPHEN G DIVERS, NPI 1760469407, CMS profile ID 353046, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1760469407?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

176 matching records · $8,517.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 176 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 176.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Puma Biotechnology, Inc. $20.6205/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059063589 CMS
Exelixis Inc. $19.4205/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044561681 CMS
Janssen Biotech, Inc. $13.5205/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988657315 CMS
Celgene Corporation $10.8305/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015589243 CMS
AstraZeneca Pharmaceuticals LP $15.5705/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011926025 CMS
MorphoSys, US Inc. $21.4805/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060328349 CMS
AbbVie Inc. $19.3105/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996706597 CMS
Novartis Pharmaceuticals Corporation $16.8705/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991555873 CMS
PFIZER INC. $15.8905/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050361425 CMS
Pharmacosmos Therapeutics Inc. $14.5705/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046246779 CMS
Celgene Corporation $7.8505/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015589227 CMS
Merck Sharp & Dohme LLC $17.0005/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048446115 CMS
PFIZER INC. $12.6505/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049186815 CMS
Celgene Corporation $11.0205/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015589219 CMS
Gilead Sciences, Inc. $16.4505/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025948221 CMS
Karyopharm Therapeutics Inc. $18.7104/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056909291 CMS
Mirati Therapeutics, Inc. $17.1004/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057989815 CMS
ADC Therapeutics America, Inc. $18.8404/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053787497 CMS
Rigel Pharmaceuticals, Inc. $13.7104/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033402059 CMS
E.R. Squibb & Sons, L.L.C. $20.7104/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015589211 CMS
Spectrum Pharmaceuticals Inc. $22.0304/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059886253 CMS
Apellis Pharmaceuticals, Inc. $20.4604/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056324751 CMS
PFIZER INC. $14.8904/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050404701 CMS
Merck Sharp & Dohme LLC $20.5704/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048446103 CMS
AstraZeneca Pharmaceuticals LP $1,387.5004/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016079561 CMS
MorphoSys, US Inc. $14.8804/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060328347 CMS
Novartis Pharmaceuticals Corporation $17.3104/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991555861 CMS
Sumitomo Pharma America, Inc. $24.1204/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030958749 CMS
Celgene Corporation $13.3304/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015589207 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.6204/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055379473 CMS
Merck Sharp & Dohme LLC $14.3803/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048873689 CMS
Novartis Pharmaceuticals Corporation $11.5703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991555857 CMS
Seagen Inc. $16.4403/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995738659 CMS
EMD Serono, Inc. $12.7403/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032302127 CMS
AstraZeneca Pharmaceuticals LP $15.7703/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011977495 CMS
ARRAY BIOPHARMA INC $25.0803/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050648337 CMS
AstraZeneca Pharmaceuticals LP $66.5303/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016220255 CMS
Novartis Pharmaceuticals Corporation $12.6303/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991555869 CMS
GlaxoSmithKline, LLC. $19.8303/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002572087 CMS
Novartis Pharmaceuticals Corporation $17.3103/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991555853 CMS
Spectrum Pharmaceuticals Inc. $14.0703/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059885371 CMS
Seagen Inc. $24.2703/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995738769 CMS
Sun Pharmaceutical Industries Inc. $12.7403/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053977557 CMS
Novartis Pharmaceuticals Corporation $16.3903/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991555845 CMS
Seagen Inc. $16.2203/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995738609 CMS
Pharmacyclics LLC, An AbbVie Company $15.5803/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998284827 CMS
Celgene Corporation $8.1503/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015589183 CMS
AVEO Pharmaceuticals, Inc. $15.3703/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049066173 CMS
AbbVie Inc. $16.3202/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996706593 CMS
Novartis Pharmaceuticals Corporation $16.5902/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991555849 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,036.24 142
PY2020 $2,698.28 97
PY2021 $3,270.49 121
PY2022 $3,974.04 166
PY2023 $8,517.27 176
PY2024 $22,052.47 180
PY2025 $12,752.53 165

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $191,903.67 11
PY2024 Principal investigator $131,334.20 24
PY2023 Principal investigator $167,431.77 30
PY2022 Recipient $15,650.00 1
PY2022 Principal investigator $50,013.00 6
PY2021 Recipient $500.05 1
PY2019 Principal investigator $562.08 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $14,534.93 10/29/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185554198
Principal investigator 1 AstraZeneca UK Limited $55,529.67 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185554206
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,036.00 05/31/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY NETWORK, LLC
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185554190
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,008.00 05/31/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY NETWORK, LLC
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185554192
Principal investigator 1 AstraZeneca Pharmaceuticals LP $66,003.67 05/31/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY NETWORK, LLC
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185554202
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185554200
Principal investigator 1 Genentech, Inc. $1,151.67 05/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211649606
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,600.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185554194
Principal investigator 1 AstraZeneca UK Limited $34,793.00 02/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185554196
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,400.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185554208
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,846.73 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185554204